Cas:6427-02-7 3-piperazin-1-ylpropan-1-ol,dihydrochloride manufacturer & supplier

We serve Chemical Name:3-piperazin-1-ylpropan-1-ol,dihydrochloride CAS:6427-02-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-piperazin-1-ylpropan-1-ol,dihydrochloride

Chemical Name:3-piperazin-1-ylpropan-1-ol,dihydrochloride
CAS.NO:6427-02-7
Synonyms:1-Piperazinepropanol 2HCl;3-(piperazin-1-yl)propan-1-ol dihydrochloride
Molecular Formula:C7H18Cl2N2O
Molecular Weight:217.13700
HS Code:2933599090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:331.6ºC at 760 mmHg
Density:N/A
Index of Refraction:
PSA:35.50000
Exact Mass:216.08000
LogP:1.14470

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1-Piperazinepropanol 2HCl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(piperazin-1-yl)propan-1-ol dihydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Piperazinepropanol 2HCl Use and application,1-Piperazinepropanol 2HCl technical grade,usp/ep/jp grade.


Related News: All of China��s provinces and territories have now been touched by the outbreak. 3-piperazin-1-ylpropan-1-ol,dihydrochloride manufacturer The third-to-market BTK inhibitor is also looking to report top-line results from a front-line trial later this year. Imbruvica could feel more pressure if that study also turns out successful. 3-piperazin-1-ylpropan-1-ol,dihydrochloride supplier This is of vital important and underlies one of the most solid principles and regulations of modern pharmacy. 3-piperazin-1-ylpropan-1-ol,dihydrochloride vendor All of China��s provinces and territories have now been touched by the outbreak. 3-piperazin-1-ylpropan-1-ol,dihydrochloride factory The third-to-market BTK inhibitor is also looking to report top-line results from a front-line trial later this year. Imbruvica could feel more pressure if that study also turns out successful.